All
- All
- CNS
- Consumer
- CRO / R&D
- Dermatology
- Diagnostics
- Hematology
- Oncology
- Vaccines
- Women's Health
Consumer
2025
Management Buy-out
Non-Disclosed
Strategic Advisor
CNS
2024
Strategic Consulting Assignment
N/A
Strategic Advisor
Consumer
2023
Acquisition by Pharmavite
$425,000,000
Financial Co-adviser
Hematology
2022
Co-Promotion Partnership for the US
$35,000,000
Strategic Advisor
Oncology
2022
Out-license to SeaGen
$700,000,000
Strategic Consultant
Hematology
2021
Capital Raise
$35,000,000
Financial Advisor
CRO / R&D
2021
Acquisition by West-Atlantic Partners
Non Disclosed
Strategic Advisor
Oncology
2020
Out-license of regional rights for Apealea to Inceptua Group
Not Disclosed
Strategic Advisor
Oncology
2020
Investment by BDI Col Ltd.
$12,000,000
Placement Agent
Diagnostics
2020
Acquisition by BioNano Genomics
$10,740,000
Strategic Advisor
Oncology
2020
Out-license of Apealea to Elevar Therapeutics
$698,000,000
Strategic Advisor
Diagnostics
2019
Series E Convertible Bridge Note
Not Disclosed
Strategic Advisor
